Former U.S. Health and Human Services Department General Counsel Robert Charrow yesterday defended his strongly worded and colorful December 2020 advisory opinion, since vacated by a court and withdrawn by HHS, that the 340B statute unambiguously requires drug manufacturers to offer 340B pricing on their products when covered entities use contract pharmacies or other distribution methods.
“I still believe my legal analysis is correct and I would issue it again,” said Charrow, senior chairman of law firm Greenberg Traurig’s health care and Food and Drug Administration practice, during a Sept. 15 webinar on the 340B program hosted by the health care news organization STAT. Charrow, a Stanford law graduate known for his trademark bowties, was appointed in 2017 by President Trump to serve as HHS General Counsel. He has served in various legal positions in Republican administrations as well as several stints in private practice.
Former U.S. Health and Human Services Department General Counsel Robert Charrow yesterday defended his strongly worded and colorful December 2020 advisory opinion, since vacated by a court and withdrawn by HHS, that the 340B statute unambiguously requires drug manufacturers to offer 340B pricing on their products when covered entities use contract pharmacies or other distribution methods.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.